RxDoctor Payments Data

Noel Rubio, MD

Internal Medicine · Chicago, ILNPI 1922036797

Payments from drug & device makers

$2,511in general payments, 2019–2025

Across 109 payments — averaging $23.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$440
  • Boehringer Ingelheim$433
  • Bayer$317
  • Lilly USA, LLC$276
  • Abbott$262
  • Amgen$233
  • plus $550 from 8 others

What the payments were for

  • Food & beverage$2,511100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,511 in reported general payments places this provider in the 85th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$52,406
Medicare patients
106
Services billed
703

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin132$196,672
OzempicSemaglutide73$121,936
Humira(Cf) PenAdalimumab11$73,190
TradjentaLinagliptin60$72,177
LinzessLinaclotide53$71,705
EliquisApixaban38$52,624
TrulicityDulaglutide25$47,361
RybelsusSemaglutide16$37,259
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$36,386
FarxigaDapagliflozin Propanediol21$31,575
Synjardy XrEmpagliflozin/Metformin Hcl21$29,831
JanuviaSitagliptin Phosphate18$24,961
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog16$21,747
Jentadueto XrLinagliptin/Metformin Hcl15$21,004
KerendiaFinerenone13$20,522

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Jentadueto Xr, Glyxambi$433$338,290239 claims
Novo NordiskOzempic, Rybelsus$440$159,19589 claims
Lilly USA, LLCTrulicity, Humalog$276$50,96736 claims
AstraZenecaFarxiga$96$31,57521 claims
BayerKerendia$317$20,52213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →